ArticleDiscover oncology2026
Bibliometric analysis of global hodgkin lymphoma research from 2002 to 2022.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHodgkin lymphoma is a rare neoplasm of the lymphatic system, representing one of the most common cancers in young adults. It is characterised by a low number of malignant cells derived from B-lymphocytes and an extensive microenvironment.
methodWe used Scopus, Web of Science and PubMed databases with search descriptors; “Hodgkin* lymphoma“ and “Hodgkin* disease”. The common bibliometric indicators were applied.
resultsWe retrieved a total of 18,304 articles within 2002 and 2022. The growth pattern showed a saturated pattern, with the linear and exponential plots coinciding. A small number of authors were responsible for the majority of the publications, with a transience index of 71.84%. The Bradford core consisted of 32 journals, with Leukemia and Lymphoma being at the top. The most productive institutions were resident in United States with the University of Texas MD Anderson Center at the helm. The United States was found to be the most productive country. Engert A. was the most productive author.
conclusionScientific production in Hodgkin lymphoma was found to be saturated with a high transience index. This study provides a reference for oncologists, epidemiologists, funders, policy decision makers, academics, and Hodgkin lymphoma researchers.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.